HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes Care"
DOI: 10.2337/dc21-1160
Abstract: OBJECTIVE To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in… read more here.
Keywords: disease bmi; group; hba1c; microvascular disease ... See more keywords